Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2017

Open Access 01-01-2017 | Laboratory Investigation

Evaluation of matrix metalloproteinase type IV-collagenases in serum of patients with tumors of the central nervous system

Authors: Serena Ricci, Elia Guadagno, Dario Bruzzese, Marialaura Del Basso De Caro, Carmela Peca, Francesco G. Sgulò, Francesco Maiuri, Angelina Di Carlo

Published in: Journal of Neuro-Oncology | Issue 2/2017

Login to get access

Abstract

The basement membrane collagen IV-degrading matrix metalloproteinases -2 and -9 (MMPs) are most often linked to the malignant phenotype of tumor cells by playing a critical role in invasion, metastasis, angiogenesis, and vasculogenesis. We verified the activity of these two MMPs in the sera of patients affected by brain tumors (20 gliomas, 28 meningiomas and 20 metastasis) by zymography. The sera of 25 healthy volunteers with no concomitant illnesses were used for controls. Zymography showed four dominant gelatinolytic bands of 240, 130, 92 (MMP-9) and 72 (MMP-2) kDa. No statistically significant variations of MMP-2 proteolytic activity between patients and healthy individuals were observed. On the contrary, MMP-9 (both monomeric and multimeric forms) lytic activities were significantly higher in tumors specimens compared to healthy controls (p < 0.001). Moreover, MMP-9 immunohistochemistry revealed: (1) a strong reactivity in neoplastic vessels of high-grade gliomas showing an inverse correlation with serum multimeric gelatinolytic activity; (2) a cytoplasmatic reactivity in meningiomas with a significantly increase in atypical meningioma compared with low-grade ones (p = 0.036); (3) a positive correlation between MMP-9 and Ki-67 (Sperman Rho coefficient r = 0.418 and p = 0.034). Our results suggest that serum and tissue MMP-9 might provide clinicians additional objective information in intracranial neoplasms. Finally, it should be possible to use MMP-9 as a target for new forms of therapy. Nevertheless, due to the small number of patients included in the study, the conclusion may not be transferable to the general population and therefore further evaluations are needed.
Literature
1.
go back to reference Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumours: current concepts and review of the literature. Neurooncology 4(4):278–299 Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumours: current concepts and review of the literature. Neurooncology 4(4):278–299
2.
go back to reference Hutter A, Schwetye KE, Bierhals AJ, McKinstry RC (2003) Brain neoplasms: epidemiology, diagnosis, and prospects for cost-effective imaging. Neuroimaging Clin N Am 13(2):237–250CrossRefPubMed Hutter A, Schwetye KE, Bierhals AJ, McKinstry RC (2003) Brain neoplasms: epidemiology, diagnosis, and prospects for cost-effective imaging. Neuroimaging Clin N Am 13(2):237–250CrossRefPubMed
3.
go back to reference Mehta M, Vogelbaum MA, Chang S, et al (2011) Neoplasms of the central nervous system. In: DeVita VT Jr, Lawrence TS, Rosenberg SA Cancer: principles and practice of oncology. 9th ed. Lippicott Williams & Wilkins, Philadelphia, pp 1700–1749 Mehta M, Vogelbaum MA, Chang S, et al (2011) Neoplasms of the central nervous system. In: DeVita VT Jr, Lawrence TS, Rosenberg SA Cancer: principles and practice of oncology. 9th ed. Lippicott Williams & Wilkins, Philadelphia, pp 1700–1749
4.
go back to reference Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109CrossRefPubMedPubMedCentral Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109CrossRefPubMedPubMedCentral
5.
go back to reference Stupp R, Tonn JC, Brada M, Pentheroudakis G (2010) ESMO guidelines working group. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v190–193CrossRefPubMed Stupp R, Tonn JC, Brada M, Pentheroudakis G (2010) ESMO guidelines working group. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v190–193CrossRefPubMed
6.
go back to reference Bertram JS (2000) The molecular biology of cancer. Mol Asp Med 21:167–223CrossRef Bertram JS (2000) The molecular biology of cancer. Mol Asp Med 21:167–223CrossRef
8.
go back to reference Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteiases: structure, function and biochemistry. Circ Res 92:827–839CrossRefPubMed Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteiases: structure, function and biochemistry. Circ Res 92:827–839CrossRefPubMed
9.
go back to reference Egeblad M, Werb Z (2002) New function for the matrix metalloproteinases in cancer progression. Nat Rev 2:161–174CrossRef Egeblad M, Werb Z (2002) New function for the matrix metalloproteinases in cancer progression. Nat Rev 2:161–174CrossRef
10.
go back to reference Hadler-Olsen E, Winberg JO, Uhlin-Hansen L (2013) Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumor Biol 34(4): 2041–2051CrossRef Hadler-Olsen E, Winberg JO, Uhlin-Hansen L (2013) Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumor Biol 34(4): 2041–2051CrossRef
11.
go back to reference Klekner Á, Virga J, Tóth J, Hortobágyi T, Dér Á, Szemcsák C, Bognár L (2013) The role of extracellular matrix components in the invasion of intracranial malignancies. Magy Onkol 57:222–231PubMed Klekner Á, Virga J, Tóth J, Hortobágyi T, Dér Á, Szemcsák C, Bognár L (2013) The role of extracellular matrix components in the invasion of intracranial malignancies. Magy Onkol 57:222–231PubMed
13.
go back to reference Klein T, Bischoff R (2011) Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41:271–290CrossRefPubMed Klein T, Bischoff R (2011) Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41:271–290CrossRefPubMed
14.
go back to reference Hadler-Olsen E, Winberg JO, Uhlin-Hansen L (2013) Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumor Biol 34:2014–2051CrossRef Hadler-Olsen E, Winberg JO, Uhlin-Hansen L (2013) Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumor Biol 34:2014–2051CrossRef
15.
go back to reference Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 72:248–254CrossRefPubMed Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 72:248–254CrossRefPubMed
16.
go back to reference Ricci S, D’Esposito V, Oriente F, Formisano P, Di Carlo A (2015) Substrate-zymography: a still worthwhile method for gelatinases analysis in biological samples. Clin Chem Lab Med. doi:10.1515/cclm-2015-0668 Ricci S, D’Esposito V, Oriente F, Formisano P, Di Carlo A (2015) Substrate-zymography: a still worthwhile method for gelatinases analysis in biological samples. Clin Chem Lab Med. doi:10.​1515/​cclm-2015-0668
17.
go back to reference Triebel S, Blaser J, Reinke H, Tschesche H (1992) A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 314:386–388CrossRefPubMed Triebel S, Blaser J, Reinke H, Tschesche H (1992) A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 314:386–388CrossRefPubMed
18.
go back to reference Yan L, Borregaard N, Kjeldesen L, Moses MA (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP and neutrophil gelatinase associated lipocalin (NGAL). J Biol Chem 276:37258–37265CrossRefPubMed Yan L, Borregaard N, Kjeldesen L, Moses MA (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP and neutrophil gelatinase associated lipocalin (NGAL). J Biol Chem 276:37258–37265CrossRefPubMed
19.
go back to reference Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL (1992) Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of pro-enzyme with stromelysin. J Biol Chem 267:4583–4591PubMed Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL (1992) Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of pro-enzyme with stromelysin. J Biol Chem 267:4583–4591PubMed
20.
go back to reference Schmidt-Hansen M, Berendse S, Hamilton W (2015) Symptomatic diagnosis of cancer of the brain and central nervous system in primary care: a systematic review. Fam Pract 6:618–623CrossRef Schmidt-Hansen M, Berendse S, Hamilton W (2015) Symptomatic diagnosis of cancer of the brain and central nervous system in primary care: a systematic review. Fam Pract 6:618–623CrossRef
21.
go back to reference Ilhan-Mutlu A, Wagner L, Preusser M (2013) Circulating biomarkers of CNS tumors: an update. Biomark Med 7:267–285CrossRefPubMed Ilhan-Mutlu A, Wagner L, Preusser M (2013) Circulating biomarkers of CNS tumors: an update. Biomark Med 7:267–285CrossRefPubMed
22.
go back to reference Ilhan-Mutlu A, Wagner L, Widhalm G, Wöhrer A, Bartsch S, Czech T, Heinzl H, Leutmezer F, Prayer D, Marosi C, Base W, Preusser M (2013) Exploratory investigation of eight circulating plasma marker in brain tumor patients. Neurosurg Rev 36:45–56CrossRefPubMed Ilhan-Mutlu A, Wagner L, Widhalm G, Wöhrer A, Bartsch S, Czech T, Heinzl H, Leutmezer F, Prayer D, Marosi C, Base W, Preusser M (2013) Exploratory investigation of eight circulating plasma marker in brain tumor patients. Neurosurg Rev 36:45–56CrossRefPubMed
23.
go back to reference Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, De Angelis LM, Holland EC (2006) YKL-40 and matrix metalloproteinase-9 as serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12:5698–5704CrossRefPubMed Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, De Angelis LM, Holland EC (2006) YKL-40 and matrix metalloproteinase-9 as serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12:5698–5704CrossRefPubMed
24.
go back to reference Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, Holland EC, Hormigo A (2011) Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. J Neurooncol 105:607–612CrossRefPubMed Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, Holland EC, Hormigo A (2011) Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. J Neurooncol 105:607–612CrossRefPubMed
25.
go back to reference Forsyth PA, Wong H, Laing TD et al (1999) Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1.MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79:1828–1835CrossRefPubMedPubMedCentral Forsyth PA, Wong H, Laing TD et al (1999) Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1.MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79:1828–1835CrossRefPubMedPubMedCentral
26.
go back to reference Vince GH, Wagner S, Pietsch T, Klein R, Goldbrunner RH, Roosen K, Tonn JC (1999) Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas. Int J Dev Neurosci 17:437–445CrossRefPubMed Vince GH, Wagner S, Pietsch T, Klein R, Goldbrunner RH, Roosen K, Tonn JC (1999) Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas. Int J Dev Neurosci 17:437–445CrossRefPubMed
27.
28.
go back to reference Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA (2008) Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 14:2378–2386CrossRefPubMed Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA (2008) Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 14:2378–2386CrossRefPubMed
29.
go back to reference Huang Q, Zhao SL, Tian XY, Li B, Li Z (2013) Increased co-expression of macrophage migration inhibitory factor and matrix metalloproteinase 9 is associated with tumour recurrence of meningioma. Int J Med Sci 10:276–285CrossRefPubMedPubMedCentral Huang Q, Zhao SL, Tian XY, Li B, Li Z (2013) Increased co-expression of macrophage migration inhibitory factor and matrix metalloproteinase 9 is associated with tumour recurrence of meningioma. Int J Med Sci 10:276–285CrossRefPubMedPubMedCentral
30.
go back to reference Das A, Tan WL, Smith DR (2003) Expression of extracellular matrix markers in benign meningiomas. Neuropathology 23:275–281CrossRefPubMed Das A, Tan WL, Smith DR (2003) Expression of extracellular matrix markers in benign meningiomas. Neuropathology 23:275–281CrossRefPubMed
31.
go back to reference Barresi V, Vitarelli E, Tuccari G, Barresi G (2011) MMP-9 expression in meningiomas: a prognostic marker for recurrence risk? J Neurooncol 102:189–196CrossRefPubMed Barresi V, Vitarelli E, Tuccari G, Barresi G (2011) MMP-9 expression in meningiomas: a prognostic marker for recurrence risk? J Neurooncol 102:189–196CrossRefPubMed
32.
go back to reference Baker-Grøndahl T, Moen BH, Arnli MB, Torseth K, Torp SH (2014) Immunohistochemical characterization of brain-invasive meningiomas. Int J Clin Exp Pathol 7:7206–7219 Baker-Grøndahl T, Moen BH, Arnli MB, Torseth K, Torp SH (2014) Immunohistochemical characterization of brain-invasive meningiomas. Int J Clin Exp Pathol 7:7206–7219
Metadata
Title
Evaluation of matrix metalloproteinase type IV-collagenases in serum of patients with tumors of the central nervous system
Authors
Serena Ricci
Elia Guadagno
Dario Bruzzese
Marialaura Del Basso De Caro
Carmela Peca
Francesco G. Sgulò
Francesco Maiuri
Angelina Di Carlo
Publication date
01-01-2017
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-016-2297-4

Other articles of this Issue 2/2017

Journal of Neuro-Oncology 2/2017 Go to the issue